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Thrombopoietin receptor (TPOR) is a cytokine receptor protein present on the cell sur-
face. The activation of TPOR by thrombopoietin (TPO) (a glycoprotein hormone) triggers 
an intracellular cascade of megakaryocytopoiesis for the formation of platelets. Recent 
studies on ex vivo megakaryocytopoiesis have evolved the possibilities of therapeutics 
uses. These findings have paved the way for the development of various TPO alterna-
tives (recombinant TPO, peptide, and non-peptide TPO mimetics), which are useful in 
regenerative medicine. However, these alternatives possess various limitations such as 
induction of autoimmune effects, high production cost, low specificity, and hence activity. 
In the present study, a novel peptidic TPO mimetic was designed through computational 
studies by studying the binding sites of TPO and TMP to TPOR and analogs of known 
mimetics. Screening of combinatorial library was done through molecular docking using 
ClusPro. These studies indicated mimetic-9 as a significant molecule since it was found 
to have better binding score of −938.8 kcal/mol with seven hydrogen bonds and a high 
number of hydrophobic interactions, than known mimetic TMP with docking score of 
−798.4  kcal/mol and TMP dimer with docking score of −811.9  kcal/mol for TPOR. 
Mimetic9-TPOR complex was further assessed by the molecular dynamics simulation, 
and their complex was found to be stable with an RMSD value of 0.091 Å. While studying 
the parameters, mimetic-9 was found to have overall good physiochemical properties 
with positive grand average hydropathy (GRAVY) score and high instability index score 
and was found to be localized in the extracellular region. The designed mimetic-9 might 
prove to be a useful lead molecule for mimicking the role of TPO for in  vitro platelet 
production with higher efficiency.
Keywords: thrombopoietin, thrombopoietin receptor, mimetic library designing, molecular docking, molecular 
dynamics simulation
inTrODUcTiOn
Blood is a vital connective tissue responsible for the transport of gases and metabolites in vertebrates. It 
consists of cellular and acellular components, such as erythrocytes (red blood cells), leukocytes (white 
blood cells), platelets (thrombocytes) (cellular components), and plasma (acellular component), 
including various types of solubilized/suspended proteins, growth factors/cytokines/hormones, 
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vitamins, minerals, and water. One of the important cellular 
 component i.e., platelets are majorly responsible for wound heal-
ing and inhibition of the bleeding. These cells stick to the locations 
of tissue damage and recruit other factors that aid hemostasis and 
healing (Kuter, 1991). During homeostasis, platelets concentra-
tion in human blood is approximately 50 ×  109  cells/L, and a 
decline in the platelets concentration for any reason (< 10 × 109 
cells/L) is considered as inadequate hemostasis that needs an 
immediate supportive measure for survival (Beutler, 1993). There 
are many conditions, such as thrombocytosis, thrombocytopenia, 
and dengue fever, which result in decreased platelet counts due 
to the destruction of platelets and bone marrow megakaryocytes 
(MKs) caused by autoantibodies and insufficient thrombopoietin 
(TPO) levels. Apart from that, there are many syndromes, such as 
gray platelet syndrome, platelet alpha-granule deficiency, which 
are associated with the dysfunctioning of platelets and not their 
concentration as such.
The adequate concentration of platelets (and other cellular 
components) is maintained by a tightly regulated hierarchy of 
various progenitors/precursors and their interactions with cor-
responding growth factors/cytokines in  vivo (Matsumura and 
Kanakura, 2002). The hematopoietic stem cells (HSCs) differ-
entiate into different progenitors, including the megakaryocyte-
erythroid progenitor (MEP) and the common myeloid progenitor 
(CMP), committed for different cell lineages. MEPs give rise to 
erythroid and megakaryocytic lineages, which produce erythro-
cytes and MKs, respectively (Woolthuis and Park, 2016). MKs 
contain a much higher concentration of DNA (64 times to the 
average concentration; 128 N). The immature MKs form mature 
MKs, which generates platelets.
In thrombocytopenia, a decrease in platelet counts elicits the 
increased levels of free TPO to restore the number and size of MKs 
leading to the increased production of platelets. The polyploidy 
of these MKs increases from 16 N to 32 N, and the production of 
platelets increases to up to 11-fold (Harker, 1968; Jackson et al., 
1984; Kuter and Rosenberg, 1990). This effect is carried out by 
TPO (Kelemen et al., 1958).
Thrombopoietin (also called c-MPL ligand) is a cytokine 
having a crucial role in proliferation and maturation of MKs. 
The primary site for the synthesis of TPO’s mRNA and protein 
is liver, while in small amounts also produced in kidney, testes, 
and brain (Shimada et  al., 1995; Stoffel et  al., 1996). TPO is 
released immediately, once synthesized. Once TPO binds to its 
thrombopoietin receptor (TPOR) (c-MPL), a cascade of signaling 
pathways is induced, which in co-operation with transcription 
factors [such as signal transducer and activator of transcription 3 
(STAT3) and STAT5] induce the proliferation and maturation of 
MKs (Drachman and Kaushansky, 1997).
Considering such an important role in the maintenance of 
platelet counts, various measures have been developed by differ-
ent research groups in the treatment of thrombocytopenia and 
the related disorders. First generation agents, including recombi-
nant TPO, were studied under various extensive clinical studies. 
However, use of recombinant TPO molecule was reported to 
induce auto immune antibodies due to structural similarities 
with endogenous TPO, and eventually, the production of these 
molecules was stopped in 1998 (Bartley et al., 1994; de Sauvage 
et al., 1994; Kuter et al., 1994; Lok et al., 1994; Kato et al., 1995; 
Kuter and Begley, 2002).
Second generation agents included recombinant TPO fusion 
proteins [e.g., Promegapoietin (TPO/IL3 fusion protein)], TPO 
peptide mimetics (e.g., Fab59, AMG531, and PEG-TPOmp), 
non-peptide TPO mimetics (e.g., Eltrombopag, AKR-501), and 
TPO agonist antibodies (e.g., minibodies and domain subclass 
converted agonist antibodies). Cwirla et  al. (1997) identified 
a 14 amino acid peptide with no sequence homology to TPO 
and can efficiently bind to TPOR. Further studies have shown 
that dimerization of this peptide might increase its biological 
activity. However, these mimetics had a short circulating half-
life. Frederickson et al. (2006) developed Fab59 by inserting the 
first peptide of this dimer into complementarity determining 
region 3 (CDR3) of the heavy chain and the second peptide into 
CDR2 of the light chain of human Fab. The increase in growth 
of TPO-dependent cell lines was equivalent to that of TPO, but 
the increase in platelet counts was 30-fold less. Peg-TPOmp 
was found to induce a dose-dependent rise in the levels of 
endogenous TPO. AMG531 or romiplostim or N-plate was the 
first TPOR agonist, which entered clinical trials; binds to TPOR 
in a manner similar to TPO and is found to increase platelet 
counts in both splenectomized and non-splenectomized 
patients. Romiplostim has been found to cause bone marrow 
fibrosis in a dose-dependent manner, which decreases if the 
therapy is discontinued. In patients with thrombocytopenia 
associated with myelodysplastic syndromes, around one-third 
of the patients experienced increased reticulin fibrosis (Teofili 
et al., 2010).
There is another approach to the second generation agents 
that includes non-peptide mimetics. For example, eltrombopag 
is a non-peptide mimetic (hydrazone small molecule), which is 
administered orally and binds to TPOR in its transmembrane 
region to activate the pathway (Erickson-Miller et  al., 2005). 
Single doses have no effect, but doses in the manner 5, 10, 20, 
30, 40 up to 10 days have been shown to increase platelet counts 
in a dose-dependent manner for doses above 30  mg. The oral 
absorption of eltrombopag has been found to be affected by some 
foods and medications. Its studies indicate no development of 
bone marrow fibrosis for up to 44 weeks, but data indicate that 
subset of patients become prone to bone marrow fibrosis when 
TPOR is stimulated. Small molecules e.g., AKR-501 or YM477 
has been found to stimulate the growth of TPO-dependent cell 
lines, increase the generation of MKs from CD34 + cells (Suzuki 
et  al., 2005). Non-peptide mimetics are known to have some 
characteristics – they activate the TPOR in a different manner 
than TPO, are highly species specific, and possess additive effect 
to TPO.
The third approach is the use of monoclonal antibodies as 
these are having the long circulating half-life, are well tolerated 
and non-immunogenic. Minibodies or VB22B sc(Fv)2 is small 
bivalent antibody fragments, having a size similar to a Fab frag-
ment, prepared by the genetic modification of variable regions 
of heavy and light chains. It binds and activates the TPOR and 
increases platelet counts (Orita et al., 2005).
In our study, a novel TPO mimetic peptide was designed using 
computational methods. Binding pockets of TPO and reported 
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mimetics are important hence a library of mimetics was created 
and analyzed using the bioinformatics tools. The 3D structure 
of extracellular domain (ECD) region of TPOR was predicted to 
study its binding potency with the peptides of the library gener-
ated, to shortlist the potent TPO mimetic. Furthermore, the sta-
bility of TPO mimetic-TPOR complex was assessed by molecular 
dynamic simulations along with the analysis of physicochemical 
properties of the lead mimetic.
MaTerials anD MeThODs
3D structure Prediction and  
assessment of TPOr
Thrombopoietin receptor binds to TPO from its ECD, so the 
amino acid sequence of ECD region was retrieved from Uniprot 
database and searched for 3D structure in protein data bank. In 
the absence of crystal structure for mammalian TPOR, the 3D 
structure was generated. Amino acid sequence of TPOR was 
searched for the identification of suitable template through Basic 
Local Alignment Search Tool (BLAST) (Camacho et al., 2008).1 
Due to unavailability of a template with higher query coverage 
and with good identity, 3D structure was generated through de 
novo method using Iterative Threading ASSEmbly Refinement 
(I-TASSER).2 I-TASSER is web-based protein 3D structure 
prediction tool based on threading approach. It simulates the 
generated structure and defines its C-score, TM-score, and active 
sites. C-score refers to a confidence level of predicted structure 
of a given protein sequences where a high C-score (range from 
−5 to 2) indicates an absolute precise quality of the predicted 
structure. TM-score is structural assessment parameter in which, 
a smaller distance between the structures is weighted high. 
TM-score defines the topology of the structure, and it shows 
that a score more than 0.5 ensures a model of absolute topology 
(Yang et al., 2015).
Generated TPOR 3D structure was further evaluated by Swiss 
model workspace.3 Swiss server analyzes the various properties 
viz. solvation energy, torsion angle energy, solvent accessibil-
ity, and atom pairwise energy. Estimate of nativeness of these 
structural properties of the model with comparable features with 
high-resolution X-ray 3D protein structures is defined by the 
QMEAN score. Overall quality of the 3D structure was defined 
by the QMEAN Z-score (Benkert et  al., 2008). Furthermore, 
TPOR structure was evaluated for its stereochemical proper-
ties through Ramachandran plot. Rampage server4 was used 
to determine the dihedral angles [phi (Φ) and psi (ψ)], and the 
number of residues lying in favored, allowed, and outlier regions 
of the protein structure. It also defines the quality of the structure, 
planarity of the peptide bond, the main chain hydrogen bond 
energy; Cα chiralities and non-bonded interactions of structure 
(Lovell et al., 2003).
1 http://blast.ncbi.nlm.nih.gov/Blast.cgi
2 http://zhanglab.ccmb.med.umich.edu/I-TASSER/
3 http://swissmodel.expasy.org/qmean/cgi/index.cgi
4 http://mordred.bioc.cam.ac.uk/~rapper/rampage.php
Mimetic library generation
A library was formed on the basis of the interaction sites of TPO-
TPOR, known mimetic TMP-TPOR, and by designing analogs of 
known TPO mimetics through the literature survey. Library was 
in silico matured by changing amino acids at different positions 
with hydrophobic amino acids and forming various combinations 
of predicted mimetics. Hydrophobic amino acids were added to 
the mimetics since they are known to play an important role in 
TPOR binding and its activation.
receptor Protein Preparation
Thrombopoietin receptor 3D structure derived through de novo 
method was prepared for molecular docking analysis using 
the protein preparation wizard (PrepWiz) in the Schrödinger 
software program (Friesner et  al., 2006). Water molecules, 
unnecessary ligand, unwanted bound ligand, and duplication 
of any chain were removed, and hydrogen atoms were added to 
the TPOR protein structure, and then structure is selected for 
energy minimization and followed by optimization for molecular 
docking analysis.
ligands 3D structure Prediction
The 3D structures of mimetics in the library were predicted by 
Pepfold3, a peptide structure prediction server.5 Pepfold3 is a 
new 3D structure generation engine. It predicts the structure of 
peptides based on the Hidden Markov model conformation sam-
pling approach (Shen et al., 2014). All mimetics were imported 
into the workspace of Pepfold3, and the project name was saved 
and allowed to run. Predicted 3D structures were saved in PDB 
format.
Molecular Docking analyses of Mimetic 
Peptide library with TPOr and  
Their evaluation
Interaction analyses of mimetics with TPOR were done using 
ClusPro protein–protein molecular docking program. ClusPro 
server is a rigid docking program based on fast Fourier trans-
formation to generate low energy interaction conformations of a 
protein–protein complex using the pairwise docking potentials. 
ClusPro clusters the interaction complexes with low energy and 
analyzes with semi-definite programming based underestima-
tion program, which identifies the stability of the interaction 
clusters using the medium-range optimization algorithm. Stable 
interaction complex is refined using Monte–Carlo simulations 
(Kozakov et al., 2010). Resulting top docking score mimetic was 
selected, and its docked complex was analyzed to determine the 
molecular interactions using the Dimplot program of Ligplot+ 
(v.1.4.5) module. Dimplot determines the involved molecular 
interactions including the hydrogen bonds and hydrophobic 
interactions, between receptor and ligand interacting complex 
(Wallace et al., 1996).
5 http://bioserv.rpbs.univ-paris-diderot.fr/services/PEP-FOLD3/
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Molecular Dynamics simulation of 
Mimetic-TPOr complex
Dynamics and stability of the complex between TPOR and short-
listed mimetic were evaluated through the molecular dynamics 
simulations using MDWeb program. MDWeb is a workspace, 
which provides standard protocols for molecular dynamics simu-
lations and to scrutinize the interactions trajectories (Hospital 
et al., 2012). The optimized structure of the complex of TPOR 
and the mimetic shortlisted from designed mimetic library on the 
basis of molecular docking was used as input data for molecular 
simulations. NAMD full MD setup was used for carrying out the 
simulation. The whole process of simulation includes cleaning of 
structure, fixing of side chains, addition of hydrogen atoms, neu-
tralization, addition of solvent box, and minimization and equi-
libration of the system to finally achieve the structure prepared 
by simulation. The equilibration of the system includes heating 
the solvent to 300 K and reducing the restraints to just protein 
backbone. These steps are carried out to provide the structure 
with the necessary conditions to study its dynamics along a span 
of time. Once the structure is prepared, the water molecules in 
it are removed to reduce the size of the system to achieve the 
dry trajectory for plotting various graphs for the analysis of the 
simulated complex structure. The structural stability, flexibility, 
and deviations per residues were assessed by the RMSD value.
Physicochemical Properties and Biological 
activity assessment of lead Mimetic
Lead mimetic was analyzed for its physicochemical properties 
and compared with the TMP. Physicochemical properties of 
mimetic-9 and TMP including molecular formula, molecular 
weight, theoretical isoelectric point (pI), the number of negative 
and positive residues, extinction coefficient, aliphatic index, 
instability index, and grand average hydropathy (GRAVY) were 
determined using the Protparam server (Gasteiger et al., 2005).6
Molecular weight, extinction coefficient, net charge, and other 
properties are required to identify the chemical nature of the pep-
tide and evaluate the binding efficiency of mimetic to a specific 
receptor. Binding efficiency of mimetic is assessed by potency 
efficiency index, which is defined by percent inhibition at a given 
compound concentration divided by its molecular weight. The 
extinction coefficient illustrates absorbance of light by a protein 
at a certain wavelength and is used to quantify the formation and 
concentration of peptides during in  vitro analyses. Instability 
index value denotes whether the peptide would be stable in vitro 
or not. The instability index estimates the stability of peptides 
from statistical analysis of experimentally defined stable and 
unstable proteins. Aliphatic index predicts the total volume occu-
pied by aliphatic side chains and indicates the thermostability of 
protein. Another important parameter that implies the stability 
of the protein is GRAVY value. It determines hydrophobicity and 
hydrophilicity of a protein by adding the hydropathy values of 
each amino acid residue and dividing by the number of amino 
acids in the protein sequence. A positive value of GRAVY indi-
cates higher hydrophobicity of proteins. Furthermore, mimetic 
6 http://web.expasy.org/protparam/
subcellular localization was determined by using the Cello 
prediction server v.2.5.7 Cello server predicts the localization in 
humans, based on the multiple n-peptide compositions through 
support vector machine (Yu et al., 2006).
resUlTs
3D structure Prediction and  
assessment of TPOr
Thrombopoietin receptor (human origin) extracellular region 
amino acids sequence of size 466 amino acids was retrieved from 
Uniprot database (Uniprot accession number Uniprotkb-P40238). 
TPOR 3D structure was predicted using I-TASSER. It generated 
five models of TPOR, which were analyzed for their properties. 
Among these models, the model-1 was shortlisted with high 
C-score (−1.03), TM-score (0.58 ±  0.14), and RMSD value of 
9.5 ± 4.6 Å. C and TM-score indicated the TPOR structure to be 
of good quality with high confidence, and RMSD value showed it 
has optimal stability and flexibility.
Furthermore, TPOR structure was evaluated for its ste-
reochemical and physiochemical properties. Its stereochemical 
properties were analyzed using Rampage. It showed 60.1% resi-
dues of the TPOR structure were in favored region, and 20.9% 
residues were in the allowed region, and 19% residues were in 
outlier region. Physiochemical properties were determined by 
Swiss server and found QMEAN score is 0.362, representing the 
overall absolute quality of the TPOR structure for the various 
properties (solvation energy, torsion angle energy, solvent acces-
sibility, and atom pair wise energy). Values for these properties 
lie in the light red to red region of QMEAN score plot of TPOR 
structure and indicate good values of physiochemical properties 
(Figure 1).
interaction analyses of TMP and  
Mimetic library with TPOr
The mimetic library was designed on the basis of binding sites of 
TPO to TPOR, TMP binding sites to TPOR, analogs of reported 
mimetics (TMP and TMP dimer), and by introducing the hydro-
phobic residues at specific positions of mimetics to enhance the 
binding affinity toward the TPOR. Library was designed for 
peptides only, and it consisted of more than 40 peptides of all 
similar structures coordinates with standard amino acids only. 
Some of the mimetics from designed library with their binding 
docking score have been shown in Table 1.
For library designing and comparative analyses, TMP was 
docked with TPOR. TPOR receptor was uploaded, and its 
unstructured terminal residues were removed, and then TMP was 
uploaded as a ligand. ClusPro runs PIPER rigid body docking 
program and rotates the mimetic ligand with 70,000 rotations at 
each grid point in x, y, z-axis about the TPOR receptor 3D grid 
with spacing 1.0 Å. Then using the clustering techniques to find 
near-native conformations along with eliminating the non-native 
clusters, the 1000 best energy conformations with the lowest 
score were clustered and among them, 30 largest clusters were 
7 http://cello.life.nctu.edu.tw/
FigUre 1 | (a) Energy minimized structure of TPOR extracellular domain region through I-TASSER (B) Ramachandran plot of the 3D structure of TPOR showing 
the favored and allowed region (81% of residues) (c) 3D structural assessment using the Swiss server showed good results with QMEAN score 0.362, for solvation 
energy, torsion angle energy, solvent accessibility, and atom pairwise energy. The plot depicts the sliders in the light red to blue region, which suggests a good 
structural quality of TPOR.
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refined by minimizing the Charmm energy of the complexes. 
The clustering of the poses starts with the lowest energy pose and 
grouping all poses within 9 Å.
ClusPro resulted in a binding score (lowest energy) of 
−798.4 kcal/mol and center binding energy score of −703.4 kcal/
mol for TMP. TMP-TPOR molecular interactions were also iden-
tified using the Dimplot and it showed; TMP interacts with TPOR 
with a total of fourteen hydrophobic interactions and forms seven 
hydrogen bonds. TMP binds to TPOR at three regions: first 
region (147–174) involving residues Gly147, Pro148, Pro151, 
Lys152, Thr155, Gly156, Pro157, Pro170, Arg174, second region 
(220–277) involving residues Pro223, Tyr227, Gln265, Phe267, 
and third region involving Phe324 of TPOR. Hydrogen bonds 
were found in between Leu6 of TMP and Gln173 of TPOR with 
2.87 Å bond length, Arg13 of TMP and Gly220 of TPOR with 
2.89 Å bond length, Ala14 of TMP and Leu221 of TPOR with 
2.80 Å bond length, Ala14 of TMP and Gln222 of TPOR with 
2.91  Å bond length, Gln8 of TMP and Gly263 of TPOR with 
TaBle 1 | Known mimetic TMP and its dimer and designed library molecular docking with TPOr results: first TMP of size 14 amino acids and TPOr 
were docked using the clusPro and resulted in energy score of −798.4 kcal/mol and compared with peptides from designed library.
serial number Peptide sequence size of peptide Binding energy score in  
kcal/mol (lowest energy)
Binding energy score in 
kcal/mol (center)
Known mimetic (TMP) IEGPTLRQWLAARA 14 −798.4 −703.4
TMP Dimer IEGPTLRQWLAARA-PEG-IEGPTLRQWLAARA 28 −811.9 −685.3
Mimetic library
Mim1 EDKRKSTQRRNH 12 −675.1 −616.8
Mim2 SCTYGAFDNMETYLF 15 −779.9 −660.5
Mim3 IILEYAGHYTLALA 15 −864.6 −690.6
Mim4 IILEYAGHISLEALDFQLH 19 −777.9 −697.8
Mim5 LTYAGVHVTSCTVGL 15 −834.3 −720.2
Mim6 ILEDRCTYAVLAARYG 16 −701.4 −679.7
Mim7 LLVYAGVHVTSICTEL 16 −825.2 −718.6
Mim8 EDKRKHTQRRNH 12 −678.1 −612.0
Mim9 IGLLFVLLAARAQWYL 16 −938.8 −792.5
Mim10 EDKRKHTQRRNH 12 −581.8 −507.1
Mimetic-9 showed the high binding energy score −938.8 kcal/mol to TPOR than TMP and its dimer.
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2.75  Å bond length, Gln8 of TMP and Leu264 of TPOR with 
3.08 Å bond length and Pro4 of TMP and Gln277 of TPOR with 
3.31 Å bond length. Furthermore, TMP dimer peptide was also 
docked with TPOR, and it resulted in a lowest binding score of 
−811.9 kcal/mol and center binding score of −685.3 kcal/mol.
After that, mimetic library was docked with TPOR using 
ClusPro, and mimetic-9 was found to have high-rank confor-
mation with a weighted lowest energy score of −938.8  kcal/
mol and center binding score of −792.5  kcal/mol (Figure  2). 
Molecular interactions involved in mimetic-9 binding to TPOR 
was determined which showed, mimetic-9 also binds to three 
regions on TPOR with more residues (18) involved in hydropho-
bic interactions and seven hydrogen bonds. Mimetic-9 binding 
regions at TPOR are: first region (146–175) with involved resi-
dues Gly147, Pro148, Pro151, Thr155, Pro157, Cys169, Pro170, 
Arg174, Pro175, second region (220–277) with involved residues 
Gly220, Gln222, Tyr227, Gly263, Phe267, Gln277, and third 
region (324–328) with involved residues Phe324, Arg326, and 
His328 (Figure 3). Hydrogen bonds were found between Leu8 
of mimetic and Gln173 of TPOR with 2.84 Å bond length, Arg11 
(amino position NH2) of mimetic with Lys152 (oxygen atom) of 
TPOR with 2.73 Å bond length, Arg11 (amine position NH1) of 
mimetic with Lys152 (oxygen atom) of TPOR with 2.66 Å bond 
length, Tyr15 of mimetic with Tyr146 of TPOR with 2.78 Å bond 
length, Gln13 (OE1 position) of mimetic with Gln265 (NE2 
position) of TPOR with 2.90  Å bond length, Gln13 (NE2) of 
mimetic with Gln265 (CD position) of TPOR with 2.73 Å bond 
length, and Glu2 of mimetic with Thr275 of TPOR with 2.90 Å 
bond length. Moreover, Ala12, Leu8, Leu4, Trp14, Ala9, Leu7, 
Ala10, Phe5, Val6, and Leu3 residues of mimetic-9 were found to 
be involved in hydrophobic interactions with TPOR. Molecular 
docking studies clearly indicated that mimetic-9 binds more 
potently with TPOR than TMP and TMP dimer. And molecular 
interactions analyses showed that mimetic-9 binds at similar 
region to TPOR as TMP binds but mimetic-9 binds with more 
strong hydrophobic interactions and with more number of amino 
acid residues of TPOR, indicates the possible reason of potent 
binding of mimetic-9 with TPOR than TMP. Docked complex of 
TPOR-mimetic-9 was further analyzed with molecular dynamics 
simulations study and for physicochemical properties.
Molecular Dynamics simulation of 
Mimetic-9 with TPOr
Dynamic nature of TPOR–mimetic-9 interactions was studied 
through the molecular dynamics simulation for 10 ns. During the 
simulation, the frames of structural deviations were captured of 
the complex. TPOR–mimetic-9 complex ran for three frames and 
showed the stable conformations of interactions. Next, RMSD 
value was calculated and found to be 0.091 Å, which suggests the 
less deviation per residue of the interaction complex and stability 
till the end of the simulation (Figure 4).
Physicochemical Properties and Biological 
activity assessment of Mimetic-9
Lead mimetic-9 was assessed for the physicochemical properties 
and compared with TMP properties (Table 2). TMP is of size 14 
amino acids and its molecular weight is 1581.8 g/mol, and extinc-
tion coefficient value is 5500 M−1cm−1. TMP was found to be of 
basic nature with pI 9.60, and an aliphatic index value of 105 and 
GRAVY score of −0.150 showed that it has a comparable region of 
aliphatic nature and hydrophilic contents. Moreover its instability 
index value of 77.0, suggests it to be an unstable protein.
Lead mimetic-9 is of size 16 amino acids and has molecular 
weight 1847.2 g/mol and an pI 8.75, which showed that it has a 
small molecular weight and basic nature. Mimetic-9 possesses the 
higher extinction coefficient value of 6990 M−1cm−1 indicating the 
presence of Tyr, Trp, and Cys in abundance. Extinction coefficient 
value illustrates the absorbance of light by mimetic and help in 
quantifying the formation and concentration of peptides. The ali-
phatic index value of 183.12 showed volume occupied by aliphatic 
side chains and GRAVY value of 1.581 suggests more volume of 
the mimetic-9 structure is hydrophobic. These properties aid to 
the isolation, physical separation, and other quantitative protein 
interactions studies of the mimetic. Importantly, mimetic-9 was 
found to be stable with instability value of 9.38. Mimetic-9 was 
FigUre 2 | Docked protein complexes of TMP-TPOr and mimetic-9-TPOr, in new cartoon view above and surf view below. (a) TPOR extracellular 
domain structure of size 466 (26–491) amino acids (blue color) interacting with known mimetic TMP (red color), (B) TPOR extracellular domain structure of size 466 
amino acids (red color) interacting with mimetic-9 (IGLLFVLLAARAQWYL) of size 16 amino acids (gray color).
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also assessed for its subcellular localization in the eukaryotes in 
the physiological environment using Cello prediction server. 
Cello prediction server showed mimetic-9 localization in mito-
chondrial, nuclear organelle, and into the extracellular region 
with a high-reliability score.
DiscUssiOn
The cytokine receptor TPOR recognized, which is regulated by its 
ligand TPO to regulate the differentiation and maturation of MKs 
to form platelets; TPO has been widely used to developing the 
methods for large-scale production of platelets, which could be 
used for the various clinical regimen. As discussed in the Section 
“Introduction,” researchers have used various strategies to 
develop different compounds mimicking TPO activities includ-
ing peptides and chemical molecules. Present studies indicate the 
designing of a novel TPO mimetic that could mimic TPO role and 
bind TPOR potently. This molecule has the potential to trigger a 
signaling cascade that leads to the proliferation and differentia-
tion of MKs into platelets.
FigUre 3 | The molecular interactions of docked protein complexes, where TPOr residues are shown in maroon color, TMP, and Mimetic-9 residues 
are shown in pink color. Hydrogen bonds are shown in the green colored dashed lines and hydrophobic interaction in comb arcs. (a) TMP interacts with TPOR 
mainly at three regions at 147–174, 220–277, and 324 amino acids with seven hydrogen bonds at 173, 220, 221, 263, 264, and 277 residues of TPOR, and 14 
hydrophobic interactions. (B) Mimetic-9 binds to TPOR more efficiently at regions 146–175, 220–277, and 324–328 amino acids with a total of seven hydrogen 
bonds at 146, 152, 173, 265, 275 residues of TPOR and 18 hydrophobic interactions.
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TaBle 2 | Physicochemical properties of lead mimetic-9 and its 
comparison with physicochemical properties of TMP.
Parameters TMP Mimetic-9
Mimetic size 14 amino acids 16 amino acids
Molecular weight 1581.8 g/mol 1847.2 g/mol
Formula C71H116N22O19 C92H143N21O19
Isoelectric point 9.60 8.75
Nature Basic Basic
Overall charge Positive (+) Positive (+)
Aliphatic index value 105 183.12
Instability value 77.0 (unstable) 9.38 (Stable)
GRAVY −0.150 1.581
Extinction coefficients 5500 M−1 cm−1 6990 M−1 cm−1
FigUre 4 | Molecular dynamics simulation plot of the TPOr–mimetic-9 complex. The plot depicts the structural deviation per residue, and RMSD value was 
found to be 0.091 Å, which suggests minimum deviation and stability of the complex.
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The 3D structure of TPOR ECD region was generated through 
de novo method using I-TASSER. TPOR structure was validated 
with its stereochemical properties, physicochemical properties, 
and other structural assessment properties. Ramachandran plot 
of TPOR structure showed that 81% residues of the structure 
were in the allowed region and also possess good value for the 
solvation energy, torsion angle energy, solvent accessibility, and 
atom pairwise energy of the structure conformations.
Next, a library of peptide mimetics was designed on the basis 
of TPO and TMP binding sites to the TPOR and their analogs. 
The mimetic library constructed by us was analyzed for their 
binding efficiency with TPOR using molecular docking and 
molecular dynamic simulations. Through molecular docking 
analyses, we first studied the TMP interaction with TPOR, and it 
showed the binding energy score of −798.4 kcal/mol with seven 
hydrogen bonds and 14 residues involved in the hydrophobic 
interactions. TMP binds to TPOR majorly at three regions at 
147–174, 220–277, and 324 amino acids. Moreover, TMP dimer 
was analyzed for its interaction with TPOR, which showed bind-
ing lowest energy score of −811.9 kcal/mol and binding energy 
score of −685.3 kcal/mol at center.
Then, constructed library was assessed for their interaction 
with TPOR. Among all molecules, mimetic-9 was found to bind 
most potently with highest binding energy score of −938.8 kcal/
mol. Mimetic-9 was also found to interact with TPOR at three 
regions 146–175, 220–277, and 324–328 amino acid positions, 
which are similar regions where TMP interacts with TPOR but 
mimetic-9 interacts with more molecular interactions. Mimetic-9 
forms 7 hydrogen bonds with TPOR, and 18 residues of TPOR 
were involved in strong hydrophobic interactions with the 
mimetic-9 (Table 1). Mimetic-9 was found to have strong hydro-
phobic interactions with more number of residues of TPOR, 
which showed more efficient binding of mimetic-9 with TPOR at 
the similar binding region as TMP.
Furthermore, the mimetic-9-TPOR complex was evaluated 
using molecular dynamic simulation to study its dynamic nature 
and stability of the complex. Molecular dynamic simulation 
analysis resulted in three frames during the run of simulation for 
10 ns, and RMSD value was found to be 0.091 Å, which suggests 
the stable conformation of an interacting complex of mimetic-9 
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and TPOR. The physicochemical properties analysis showed that 
mimetic-9 is of fundamental nature with aliphatic inner side 
chain region, which indicates its thermostability at a wide range 
of temperature. GRAVY value represents the hydrophilicity and 
hydrophobicity characteristics of the mimetic through a scale 
formed on the basis of the experimental literature of hydropathy 
values of each amino acids side chains. The positive GRAVY score 
of mimetic-9 indicates its potential hydrophobic residue content.
In vitro stability of TMP and mimetic-9 was also analyzed 
by determining the instability index value. Instability index 
value estimated that TMP is unstable in vitro, and importantly 
mimetic-9 was found to be a stable protein from statistical 
analysis of experimentally defined stable and unstable proteins. 
Also, mimetic-9 was found to be majorly localized in the extracel-
lular region, and since TPOR is a surface receptor, mimetic-9 at 
extracellular region can bind more efficiently, which is another 
suitable characteristic of the mimetic.
cOnclUsiOn
In the present work, a novel TPO mimetic was designed, and 
it was compared with previously reported TMP for interaction 
with TPOR using the molecular docking simulation analyses and 
was found to be more potent than TMP. Novel Mimetic-9-TPOR 
complex showed a stable binding with an RMSD value of 0.091 Å 
through molecular dynamics simulation. Furthermore, phys-
icochemical properties of mimetic-9 showed that it is a stable 
protein with high instability index value and good GRAVY score. 
Moreover, it is predominantly localized to an extracellular region, 
a prerequisite property for mimetic to interact with cell surface 
receptor TPOR.
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